Comparison of Efficacy of Cannabinoids versus Commercial Oral Care Products in Reducing Bacterial Content from Dental Plaque: A Preliminary Observation.
antibacterial
cannabinoids
dental plaque
oral care products
personalized dental care
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
29 Jan 2020
29 Jan 2020
Historique:
entrez:
11
2
2020
pubmed:
11
2
2020
medline:
11
2
2020
Statut:
epublish
Résumé
Background Dental plaque is a complex biofilm that gets formed on the teeth and acts as a reservoir of different microbes. It is the root cause for the occurrence of several dental problems and diseases, including cavities, bad breath, bleeding gums, tooth decay, and tooth loss. Therefore, it should be regularly removed using suitable oral care aids. Objectives The present study compared the efficacy of oral care products and cannabinoids in reducing the bacterial content of dental plaques. Methods Sixty adults aged 18 to 45 years were categorized into six groups based on the Dutch periodontal screening index. Dental plaques of the adults were collected using paro-toothpick sticks and spread on two Petri dishes, each with four divisions. On Petri dish-A, cannabidiol (CBD), cannabichromene (CBC), cannabinol (CBN), and cannabigerol (CBG) were used, and on Petri dish-B, cannabigerolic acid (CBGA), Oral B, Colgate, and Cannabite F (a toothpaste formulation of pomegranate and algae) were used. The Petri dishes were sealed and incubated, followed by counting the number of colonies. Results By evaluating the colony count of the dental bacteria isolated from six groups, it was found that cannabinoids were more effective in reducing the bacterial colony count in dental plaques as compared to the well-established synthetic oral care products such as Oral B and Colgate. Conclusion Cannabinoids have the potential to be used as an effective antibacterial agent against dental plaque-associated bacteria. Moreover, it provides a safer alternative for synthetic antibiotics to reduce the development of drug resistance.
Identifiants
pubmed: 32038896
doi: 10.7759/cureus.6809
pmc: PMC6991146
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e6809Informations de copyright
Copyright © 2020, Stahl et al.
Déclaration de conflit d'intérêts
Veronica Stahl have pending patents (in process) for application of cannabinoids in dental care, personalization and treatments. . Veronica Stahl also has a financial interest in CannIBite.
Références
Front Microbiol. 2016 Jan 14;6:1529
pubmed: 26834707
Pathogens. 2019 Feb 01;8(1):
pubmed: 30717107
Sci Rep. 2018 Dec 6;8(1):17696
pubmed: 30523307
Pharm Weekbl Sci. 1992 Dec 11;14(6):353-6
pubmed: 1475174
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
pubmed: 2308954
J Ethnopharmacol. 2006 Dec 6;108(3):414-22
pubmed: 16879937
Fitoterapia. 2010 Jul;81(5):413-9
pubmed: 19969046
Molecules. 2019 Jul 15;24(14):
pubmed: 31311157
J Forensic Sci. 2010 Sep;55(5):1209-17
pubmed: 20487147
Mar Drugs. 2018 Aug 27;16(9):
pubmed: 30150576
Trends Neurosci. 1990 Oct;13(10):420-3
pubmed: 1700516
Anc Sci Life. 2011 Oct;31(2):49-51
pubmed: 23284205
J Herb Pharmacother. 2006;6(2):79-92
pubmed: 17182487
Front Cell Infect Microbiol. 2019 Sep 10;9:324
pubmed: 31552202
J Nat Prod. 1980 Mar-Apr;43(2):169-234
pubmed: 6991645
Int J Oral Sci. 2009 Dec;1(4):196-206
pubmed: 20690423
Eur J Pharm Biopharm. 2000 Jul;50(1):83-99
pubmed: 10840194
Int J Clin Pediatr Dent. 2017 Apr-Jun;10(2):152-157
pubmed: 28890615
J Periodontol. 2011 Nov;82(11):1602-7
pubmed: 21513470
Pharmacogn Rev. 2015 Jul-Dec;9(18):87-92
pubmed: 26392704
Pak J Pharm Sci. 1995 Jan;8(1):29-38
pubmed: 16414764
J Nat Prod. 2008 Aug;71(8):1427-30
pubmed: 18681481
Front Plant Sci. 2016 Feb 04;7:19
pubmed: 26870049
Br J Pharmacol. 2006 Jan;147 Suppl 1:S163-71
pubmed: 16402100
BMC Microbiol. 2015 Aug 12;15:159
pubmed: 26264142